Patents by Inventor Ulrik Bjerl Nielsen

Ulrik Bjerl Nielsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bi-Specific Fusion Proteins
    Publication number: 20230322951
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: May 3, 2023
    Publication date: October 12, 2023
    Applicant: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-specific fusion proteins
    Patent number: 11673970
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: June 13, 2023
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-Specific Fusion Proteins
    Publication number: 20210040233
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-specific fusion proteins
    Patent number: 10858450
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: December 8, 2020
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-Specific Fusion Proteins
    Publication number: 20180237540
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: April 19, 2018
    Publication date: August 23, 2018
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-specific fusion proteins
    Patent number: 9982060
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: May 29, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre